DACOPLICE® Home
Clinical Information
Support & Services
References:
- Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454-1466.
- Mok TS, Cheng Y, Zhou X, et al. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021;81(2):257-266.
- Local Prescribing Document for DACOPLICE®. LPD Version 4. Pfizer India_LPDDAC042021.
Please click on Prescribing Information link to view safety and adverse events information of DACOPLICE®
PP-DAC-IND-0093 22-07-2021